Valneva SE (VLA)
Euronext
Closed
Oct 7, 2026
Day's Range
2.5352 wk Range
2.03Overview - VLA - Valneva SE
Key Statistics
Valuation
Enterprise Value
593.16M
P/E (Trailing)
‪70.64‬
P/E (Forward)
‪17.27‬
PEG Ratio
‪17.27‬
Price / Sales (TTM)
‪3.52‬
Price / Book
‪6.21‬
EV / EBITDA
‪-6.00‬
Profitability
Gross Margin
‪4.57%‬
Profit Margin
‪-110.29%‬
Operating Margin
‪-74.91%‬
Return on Assets
‪-16.68%‬
Return on Equity
‪-117.84%‬
Ownership
Shares Outstanding
204.23M
Float
157.26M
Held by Insiders
‪10.72%‬
Held by Institutions
‪23.87%‬
Price stats
Beta
‪1.37‬
50-Day Avg
‪2.63‬
200-Day Avg
‪3.09‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪€ 6.19‬Market Cap - VLA - Valneva SE
Peers - VLA - Valneva SE
Peer Comparison
Compared with companies in Biotechnology listed on Euronext.
Profile Summary - VLA - Valneva SE
About
Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercial portfolio features three key vaccines: IXIARO®, for Japanese encephalitis;…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
